EN DE
STOCK COMPARISON

Fresenius SE & Co. KGaA vs HCA Healthcare: Fair Value & Quality

Both stocks run through our valuation models. Here is how Fresenius SE & Co. KGaA (FRE) and HCA Healthcare (HCA) compare, as of Aug 8, 2026.

As of Aug 8, 2026, Fair Value Calculator sees HCA Healthcare as the more attractively valued of the two: Fresenius SE & Co. KGaA trades at €46.68 versus a fair value of €32.15 (-31%), while HCA Healthcare trades at $409 versus $555 (+36%).
Fresenius SE & Co. KGaA
FRE.XETRA · EUR · Health Care
-31%
upside to fair value
overvalued
Price€46.68
Fair Value€32.15
Quality59/100
HCA Healthcare
HCA · USD · Health Care
+36%
upside to fair value
undervalued
Price$409
Fair Value$555
Quality62/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Fresenius SE & Co. KGaAHCA Healthcare
Valuation
15.6×P/E (TTM)12.5×
1.18×P/S (TTM)1.06×
1.42×P/B
11.5×EV/EBITDA7.8×
0.77×PEG1.18×
2.5%Dividend yield0.8%
€1.05Dividend per share$2.94
Profitability
6%Net margin9%
10%Operating margin15%
8%Return on equity136%
3%Return on assets12%
Growth
2%Revenue growth (YoY)4%
2.4%Avg. growth/yr (3Y)7.9%
-8.8%Avg. growth/yr (5Y)8.0%
Balance & size
0.48×Debt / equity
$27BMarket cap$81B
weakGrowth qualityhealthy

HCA Healthcare leads: 2 to 10 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Fresenius SE & Co. KGaAof which business quality 55 · market factors 61 HCA Healthcareof which business quality 66 · market factors 45
ProfitabilityMargins and returns on capital today
32
76
Quality GrowthAre margins and returns improving?
57
61
CashflowEarnings quality: real cash, not paper profit
50
62
Fin. StrengthBalance sheet, leverage, solvency risk
45
39
InvestmentDisciplined investing over empire-building
92
75
Low VolatilityCalm price path (market factor)
78
59
MomentumPrice trend over the last 3–12 months (market factor)
50
38
52W MomentumDistance to the 52-week high (market factor)
61
43
Net IssuanceBuybacks instead of dilution
81
100

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Fresenius SE & Co. KGaA

DCF Models€27.07
Earnings-Based€17.93
Dividend Discount€16.93
Multiples€41.52
Asset-Based€22.73
Growth DCF€25.33
Economic Profit€23.30
Growth Earnings€35.84

22 of 25 models see the stock below the current price.

HCA Healthcare

DCF Models$519
Earnings-Based$289
Dividend Discount$53.85
Multiples$612
Growth DCF$540
Economic Profit$419
Growth Earnings$478

6 of 23 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Fresenius SE & Co. KGaA
Bear €27.44Fair Value €32.15Bull €48.50
€46.68 = current price (white tick)
HCA Healthcare
Bear $270Fair Value $555Bull $841
$409 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Fresenius SE & Co. KGaA · Health Care

Quality score59 · above median
Fair value upside-31% · below median

HCA Healthcare · Health Care

Quality score62 · Top 25%
Fair value upside+36% · Top 25%

Bottom line

As of Aug 8, 2026, Fair Value Calculator sees HCA Healthcare as the more attractively valued of the two: Fresenius SE & Co. KGaA trades at €46.68 versus a fair value of €32.15 (-31%), while HCA Healthcare trades at $409 versus $555 (+36%).

HCA Healthcare has the higher quality score (62/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.